Sign in

    Catherine

    Research Analyst at Citizens JMP Securities, LLC

    Catherine Okoukoni is an Analyst at Citizens JMP Securities, LLC, contributing to equity research with a focus on covered sectors determined by the firm’s client base. While specific companies and performance metrics such as success rates or rankings are not publicly available, her current role at Citizens JMP Securities builds on the firm's established presence in investment banking and research. Catherine's precise career timeline, previous professional experience, and details on licenses or credentials remain undisclosed through available sources. Her professional profile reflects active analyst responsibilities at Citizens JMP Securities, where she is accessible via her LinkedIn presence.

    Catherine's questions to Altimmune (ALT) leadership

    Catherine's questions to Altimmune (ALT) leadership • Q1 2025

    Question

    Catherine of Citizens JMP, on behalf of John Wolleben, asked about the expected speed of action for pemvidutide compared to competitors like survodutide and which biomarkers might show the most change between 24 and 48 weeks.

    Answer

    An Altimmune executive attributed pemvidutide's superior speed and potency to its 1:1 GLP-1/glucagon ratio, which contains more glucagon than competitors and drives faster liver fat reduction, enabling a 24-week readout. The executive expects biomarker responses, particularly with ELF and FibroScan, to continue improving between the 24-week and 48-week time points, further validating the drug's effect.

    Ask Fintool Equity Research AI

    Catherine's questions to OCULAR THERAPEUTIX (OCUL) leadership

    Catherine's questions to OCULAR THERAPEUTIX (OCUL) leadership • Q3 2024

    Question

    Catherine, on behalf of Jonathan Wolleben, asked if Ocular was reiterating its 2024 guidance for DEXTENZA and requested commentary on how the 2025 CMS rule will affect DEXTENZA's pricing.

    Answer

    Chief Commercial Officer Steve Meyers confirmed that DEXTENZA remains on track to meet its previously issued guidance. He also expressed that the company is 'very pleased' with the CMS rule, as it reconfirms separate payment for DEXTENZA in the hospital outpatient department (HOPD) setting for 2025.

    Ask Fintool Equity Research AI